2024-510810-33-00招募中3 期
An Open-Label Long-Term Phase III Extension Study to Assess the Long-Term Safety and Tolerability of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5)
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 46
- 试验地点
- 21
- 主要终点
- Assessment of treatment emergent AEs (TEAEs), clinical laboratory parameters, vital signs, and 12-lead ECGs.
研究概览
简要总结
To assess the long-term safety of dexpramipexole 150 mg BID in participants who completed either of the Phase III studies EXHALE-2 or EXHALE-3.
入排标准
- 年龄范围
- 0 years 至 65+ years（0-17 Years, 65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Participants who completed the double-blind study intervention treatment period during either of the Phase III studies EXHALE-2 or EXHALE-
- •Signed informed consent form (ICF) and assent form as appropriate.
- •Negative urine pregnancy test for women of childbearing potential (WOCBP; after menarche) at the Baseline Visit/Day
- •WOCBP (after menarche) must use either of the following methods of birth control, from the Baseline Visit/Day 1 through the End of Study Visit: a. A highly effective form of birth control (confirmed by the investigator). Highly effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective intrauterine device (IUD), IUD/intrauterine system, levonorgestrel intrauterine system, or oral contraceptive. Or b. Two protocol acceptable methods of contraception in tandem. Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for ≥12 months prior to the planned date of the Baseline Visit/Day 1 without an alternative medical cause. The following age specific requirements apply: c. Women <50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone levels in the postmenopausal range. d. Women ≥50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment.
排除标准
- •Clinically significant change in health status during either of the Phase III studies EXHALE-2 or EXHALE-3 which in the opinion of the investigator would make the participant unsuitable for participation in this study.
- •Participants with allergy/intolerance to dexpramipexole or any of its excipients.
- •Participants who met permanent discontinuation criteria or permanently discontinued study treatment for any reason in either of the Phase III studies EXHALE-2 or EXHALE-
- •Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days
- •Pregnant or breastfeeding women.
- •Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide).
结局指标
主要结局
Assessment of treatment emergent AEs (TEAEs), clinical laboratory parameters, vital signs, and 12-lead ECGs.
Assessment of treatment emergent AEs (TEAEs), clinical laboratory parameters, vital signs, and 12-lead ECGs.
次要结局
- Annualized rate of severe asthma exacerbations over 52 weeks.
- Asthma Control Questionnaire-6 (ACQ-6), change from baseline, at Weeks 16, 32, and 52.
- Absolute eosinophil counts (AEC), change from baseline, at Weeks 16, 32, and 52.
研究者
Andrew Friedman
Scientific
Areteia Therapeutics Inc.
研究点 (21)
Loading locations...
相似试验
终止
3 期
Phase III Long-Term Extension Study With DexpramipexoleEosinophilic AsthmaNCT06388889Areteia Therapeutics509
已完成
3 期
Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat HeartburnGastroesophageal Reflux DiseaseNCT00255190Takeda591
终止
2 期
Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension StudySystemic Lupus ErythematosusNCT05430854Amgen155
No Longer Available
不适用
Extension Study of Drisapersen in DMD SubjectsDuchenne Muscular DystrophyNCT02636686BioMarin Pharmaceutical
进行中（未招募）
3 期
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary AtresiaBiliary AtresiaNCT05426733Albireo, an Ipsen Company180